A Case of Acute Problem Gambling Associated With Agomelatine

[1]  R. Murray,et al.  Should psychiatrists be more cautious about the long-term prophylactic use of antipsychotics? , 2016, British Journal of Psychiatry.

[2]  Kenneth G. C. Smith,et al.  Peripheral Immune Cell Populations Associated with Cognitive Deficits and Negative Symptoms of Treatment-Resistant Schizophrenia , 2016, PloS one.

[3]  P. Jolliet,et al.  Pathological Gambling Associated With Aripiprazole or Dopamine Replacement Therapy , 2015, Journal of clinical psychopharmacology.

[4]  Egorov Ay.  [The use of agomelatine (valdoxan) in gambling therapy: a pilot study]. , 2015 .

[5]  Tiebing Liang,et al.  COMT Associations with Disordered Gambling and Drinking Measures , 2015, Journal of Gambling Studies.

[6]  J. Sanjuán,et al.  Premorbid adjustment and clinical correlates of cognitive impairment in first-episode psychosis. The PEPsCog Study , 2015, Schizophrenia Research.

[7]  Bruce G. Pollock,et al.  Prediction of working memory performance in schizophrenia by plasma ratio of clozapine to N-desmethylclozapine. , 2015, The American journal of psychiatry.

[8]  M. Millan,et al.  Agomelatine: mechanism of action and pharmacological profile in relation to antidepressant properties , 2014, British journal of pharmacology.

[9]  K. Blum,et al.  The genetics of problem and pathological gambling: a systematic review. , 2014, Current pharmaceutical design.

[10]  Godfrey D Pearlson,et al.  Neuropsychological impairments in schizophrenia and psychotic bipolar disorder: findings from the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP) study. , 2013, The American journal of psychiatry.

[11]  J. Kennedy,et al.  Association of functional variants in the dopamine D2-like receptors with risk for gambling behaviour in healthy Caucasian subjects , 2010, Biological Psychology.

[12]  M. Durand,et al.  Cognitive effects of antipsychotic dosage and polypharmacy: a study with the BACS in patients with schizophrenia and schizoaffective disorder , 2010, Journal of psychopharmacology.

[13]  V. Manolopoulos,et al.  Association of polymorphisms of the serotonergic system with smoking initiation in Caucasians. , 2010, Drug and alcohol dependence.

[14]  Richie Poulton,et al.  Static and dynamic cognitive deficits in childhood preceding adult schizophrenia: a 30-year study. , 2010, The American journal of psychiatry.

[15]  A. Prus,et al.  The role of M1 muscarinic cholinergic receptors in the discriminative stimulus properties of N-desmethylclozapine and the atypical antipsychotic drug clozapine in rats , 2009, Psychopharmacology.

[16]  C. Correll,et al.  Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. , 2009, Schizophrenia bulletin.

[17]  Ming D. Li,et al.  A functional polymorphism, rs6280, in DRD3 is significantly associated with nicotine dependence in European‐American smokers , 2008, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[18]  Philip D. Harvey,et al.  Norms and standardization of the Brief Assessment of Cognition in Schizophrenia (BACS) , 2008, Schizophrenia Research.

[19]  J. Lieberman,et al.  Efficiency of the CATIE and BACS neuropsychological batteries in assessing cognitive effects of antipsychotic treatments in schizophrenia , 2008, Journal of the International Neuropsychological Society.

[20]  A. Lang,et al.  Factors associated with dopaminergic drug-related pathological gambling in Parkinson disease. , 2007, Archives of neurology.

[21]  Philip D. Harvey,et al.  The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery , 2004, Schizophrenia Research.

[22]  Peter B. Jones,et al.  The Clinical Global Impression–Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia , 2003, Acta psychiatrica Scandinavica. Supplementum.

[23]  J. Gold,et al.  Another view of therapy for cognition in schizophrenia , 2002, Biological Psychiatry.

[24]  S. McGurk.  The effects of clozapine on cognitive functioning in schizophrenia. , 1999, The Journal of clinical psychiatry.

[25]  H. Meltzer,et al.  Effects of clozapine on cognitive function in schizophrenia. , 1994, The Journal of clinical psychiatry.

[26]  H. Meltzer,et al.  The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. , 1999, Schizophrenia bulletin.